Experienced in Hairy Cell Leukemia (HCL)

Dr. Dustin E. Stevenson

Hematology Oncology | Hematology | Oncology
Austin J Ma MD A Professional Corporation
8339 Brimhall Rd, Suite 1302, 
Bakersfield, CA 
Experienced in Hairy Cell Leukemia (HCL)
Austin J Ma MD A Professional Corporation
8339 Brimhall Rd, Suite 1302, 
Bakersfield, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dustin Stevenson is a Hematologist Oncology specialist and a Hematologist in Bakersfield, California. Dr. Stevenson is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Essential Thrombocythemia, Breast Cancer, Colorectal Cancer, and Deep Vein Thrombosis.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

AUSTIN J MA MD A PROFESSIONAL CORPORATION
8339 Brimhall Rd, Suite 1302, Bakersfield, CA 93312

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 24, 2025
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Alan D. Cartmell
Experienced in Hairy Cell Leukemia (HCL)
Dr. Alan D. Cartmell
Hematology | Palliative Medicine
Experienced in Hairy Cell Leukemia (HCL)
Dr. Alan D. Cartmell
Hematology | Palliative Medicine

Ravi Patel, M.D., Inc.

6501 Truxtun Ave, 
Bakersfield, CA 
 (3.3 miles away)
661-322-2206
Languages Spoken:
English
See accepted insurances
Accepting New Patients

I believe the best care can be achieved only when patients understand their conditions properly and are fully satisfied with the care they receive. Through effective education, patients are empowered to partner in their care and achieve their health priorities. Dr. Cartmell is rated as an Advanced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Bone Tumor, Anemia, Breast Cancer, and Leukocytosis.

Pradip K. Rustagi
Experienced in Hairy Cell Leukemia (HCL)
Dr. Pradip K. Rustagi
Hematology | Oncology
Experienced in Hairy Cell Leukemia (HCL)
Dr. Pradip K. Rustagi
Hematology | Oncology

Ravi Patel, M.D., Inc.

6501 Truxtun Ave, 
Bakersfield, CA 
 (3.3 miles away)
661-322-2206
Languages Spoken:
English
See accepted insurances

Pradip Rustagi is a Hematologist and an Oncologist in Bakersfield, California. Dr. Rustagi is rated as an Advanced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Thrombocytopenia, Classical Hodgkin Lymphoma, Hodgkin Lymphoma, and Breast Cancer.

Experienced in Hairy Cell Leukemia (HCL)
Dr. Samuel S. Kuo
Hematology Oncology | Geriatrics | Hematology
Experienced in Hairy Cell Leukemia (HCL)
Dr. Samuel S. Kuo
Hematology Oncology | Geriatrics | Hematology

Altura Centers For Health

1101 N Cherry St, 
Tulare, CA 
 (58.6 miles away)
559-686-9097
Languages Spoken:
English
See accepted insurances

Samuel Kuo is a Hematologist Oncology specialist and a Geriatrics provider in Tulare, California. Dr. Kuo is rated as an Advanced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Anemia, Thrombocytopenia, Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stevenson's expertise for a condition
ConditionClose
      View All 17 Advanced Conditions
      View All 120 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile